The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2004 AND VI 22 AND IP 4
Results: 10
1
2
Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds.
- Published in:
- 2004
- By:
- Publication type:
- journal article
3
Cost-effectiveness of clopidogrel.
- Published in:
- 2004
- By:
- Publication type:
- research
4
Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
- Published in:
- 2004
- By:
- Publication type:
- journal article
5
Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.
- Published in:
- 2004
- By:
- Publication type:
- journal article
6
A Review of Self-Report Instruments Measuring Health-Related Work Productivity: A Patient-Reported Outcomes Perspective.
- Published in:
- PharmacoEconomics, 2004, v. 22, n. 4, p. 225, doi. 10.2165/00019053-200422040-00002
- By:
- Publication type:
- Article
7
Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing.
- Published in:
- 2004
- By:
- Publication type:
- journal article
8
Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C.
- Published in:
- PharmacoEconomics, 2004, v. 22, n. 4, p. 257, doi. 10.2165/00019053-200422040-00004
- By:
- Publication type:
- Article
9
The NICE reference case requirement: implications for drug manufacturers and health systems.
- Published in:
- 2004
- By:
- Publication type:
- Letter
10
The NICE reference case requirement: more pain for what, if any, gain?
- Published in:
- 2004
- By:
- Publication type:
- commentary